Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca paid $100M upfront with up to $1.145B in milestones plus tiered double-digit royalties for the most advanced oral Syk inhibitor in RA —…
$800 million of the $1.2 billion headline consisted of back-end sales milestones; such post-launch milestones are an old trick used by biotech executives to…
AstraZeneca returned fostamatinib rights to Rigel after disappointing OSKIRA Phase 3 results in RA — retrospectively framing the original $1.245B deal as a…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AstraZeneca/Rigel exclusive worldwide license for fostamatinib: $100M upfront + up to $345M dev/reg/first-sale milestones + up to $800M sales milestones + tiered double-digit royalties. Includes Rigel's broader Syk inhibitor portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Rigel Pharmaceuticals, Inc. (Fostamatinib license) (this deal) | 2010 | $1.2B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2010 deals · AstraZeneca PLC deals · Immunology deals